Long-term Outcome After Edoxaban Versus Vitamin K Antagonists for Acute VTE

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1,200 enrolled

Overview

The HOKUSAI post VTE study contains of two different research questions; one on the long term outcomes of deep vein thrombosis and one on the long term effects of pulmonary embolism, post thrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension (CTEPH) respectively. Our aim of the study is to compare the long term outcomes along with the quality of life assessment of VTE in a group treated with heparin+VKA versus a group treated with heparin+edoxaban in the acute setting.

Study Type

OBSERVATIONAL

Enrollment

1,200

Conditions

Venous Thromboembolic Disease Post Thrombotic Syndrome Chronic Thromboembolic Pulmonary Hypertension Quality of Life

Interventions

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Participant in the HOKUSAI VTE trial Exclusion Criteria: * None

Locations (1)

Academisch Medisch Centrum

Amsterdam, Netherlands

RECRUITING

Outcomes

Primary Outcomes

Post thrombotic syndrome (PTS)

PTS according to Villalta

Time frame: up to 10 years

Secondary Outcomes

Chronic thromboembolic pulmonary hypertension (CTEPH)

according to clinical and objective criteria

Time frame: up to 10 years

Central Contacts

Ingrid Bistervels, MD

CONTACT

+31205665976 i.m.bistervels@amc.uva.nl

Roisin Bavalia, MD

CONTACT

0031 205667516 r.bavalia@amc.uva.nl

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.